Suven Life Sciences secures four product patents for their NCE's

In Australia, Eurasia, Israel and USA

Suven Life Sciences announced that they secured patents in Australia, Eurasia, Israel and USA to their New Chemical Entities for CNS therapy through mechanism of action - H3 Inverse agonist and these patents are valid until 2032, 2030, 2031 and 2032 respectively.

Powered by Capital Market - Live News